产品详情
Targets
Target | Value |
---|---|
ErbB2 | IC50: 9.2nM |
EGFR | IC50: 10.8nM |
ErbB4 | IC50: 367nM |
c-Src | IC50: 3.5μM |
C-Raf-1 | IC50: >10μM |
MEK | IC50: >10μM |
ERK | IC50: >10μM |
c-Fms | IC50: >10μM |
CDK1 | IC50: >10μM |
CDK2 | IC50: >10μM |
p38 | IC50: >10μM |
Tie-2 | IC50: >10μM |
VEGFR2 | IC50: >10μM |
In vitro (25°C) | DMSO | 99 mg/mL (170.37 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 2% DMSO+30% PEG 300+5% Tween 80+ddH2O | 9 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 17.21 mL | 86.04 mL | 172.09 mL |
0.5 mM | 3.44 mL | 17.21 mL | 34.42 mL |
1 mM | 1.72 mL | 8.6 mL | 17.21 mL |
5 mM | 0.34 mL | 1.72 mL | 3.44 mL |
*The above data is based on the productmolecular weight 581.1 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A11752 |
---|---|
M. Wt | 581.1 |
Formula | C29H26ClFN4O4S |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 231277-92-2 |
SMILES | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl |
产品资料
产品标签
Product Questions
Product Questions
Canertinib (CI-1033)
Canertinib (CI-1033)是一种不可逆的酪氨酸激酶抑制剂,对EGFR(IC50 0.8 nM),HER-2(IC50 19 nM)和ErbB-4(IC50 7 nM)…
Mubritinib (TAK 165)
Mubritinib (TAK 165)是一种有效的EGFR和p34cdc2抑制剂,IC50分别为6 nM和0.2 ?M。Mubritinib(TAK 165)也抑制p33cdk2和p33cd…
AG-18 (Tyrphostin 23)
AG-18 (Tyrphostin 23)是人表皮癌细胞系A431中的表皮生长因子(EGF)受体激酶抑制剂,IC50值为35M。
ARRY-543 (Varlitinib, ASLAN001)
ARRY-543 (Varlitinib,ASLAN001)是一种新型口服ErbB家族抑制剂,与批准的ErbB抑制剂不同,它直接或间接靶向ErbB家…
Pelitinib (EKB-569)
Pelitinib (EKB-569)是一种有效的,不可逆EGFR抑制剂,IC50为38.5 nM
PF299804 (Dacomitinib, PF299)
PF299804是一种有效的,可口服的酪氨酸激酶人表皮生长因子受体(HER)1(EGFR),HER2和HER4不可逆抑制剂。
ASP8273 (Naquotinib)
ASP8273 (Naquotinib)是不可逆的,第三代,选择性突变的表皮生长因子受体(EGFR)抑制剂,具有潜在的抗肿瘤…